@adytum_official: GLP-1 receptor agonists are known for diabetes and weight, but a fast-growing body of research suggests they’re also broadly anti-inflammatory and immune-modulating. A 2025 systematic review described effects well beyond metabolism, including emerging interest in autoimmune and neurological conditions. The most direct evidence for MCAS so far is a single 2025 retrospective case series: 47 patients with treatment-resistant MCAS, 89% of whom showed clinical benefit, often within hours to days, across inflammatory, gastrointestinal, neurologic, and autonomic symptoms. Mechanistically, mast cells carry GLP-1 receptors, and these drugs dampen inflammatory pathways like TNF-alpha and NF-kB, which may explain it. The limitations matter and the hype skips them: this was retrospective, single-group, with NO control or placebo, and the authors themselves state that randomized controlled trials are needed before any of this is established. GLP-1 medications are serious prescription drugs with real side effects, real costs, and access issues, and they are NOT a proven or standard MCAS treatment. This is a promising research lead, not a recommendation. I’m not a doctor or scientist. Talk to a clinician who knows your history. Has anyone here been on a GLP-1 and noticed other symptoms change? Curious what you actually experienced. Sources: Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR. Utility of GLP-1 receptor agonists in mast cell activation syndrome. Am J Med Sci. 2025;370(4):377-382. DOI: 10.1016/j.amjms.2025.07.006. Patel S, Niazi SK. Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics17081036. Alharbi SH. Anti-inflammatory role of GLP-1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024. DOI: 10.1177/20420188231222367. #mcas #mastcellactivationsyndrome #glp1 #semiglutide #autoimmune

Adytum

Open In TikTok:

Region: US

Tuesday 23 June 2026 01:21:12 GMT